\n<\/p>\n
Net profits drop 46% to HK$612 million with final
\ndividend HK$0.05\/share<\/b><\/p>\n
\n
<\/p>\n
Adjust product mix actively; Strive for innovative
\nbreakthroughs<\/b><\/p>\n
\n
\n
\n
<\/p>\n
Results summary:<\/b>
\n
<\/p>\n
\n
<\/p>\n
HONG KONG SAR –\u00a0Media OutReach<\/a>\u00a0–\u00a030 March
During the year, the
The Board of directors resolved to pay a final dividend of HK$0.05 per
During the year, revenue of ampoule products amounted to HK$863 million,
Following along the lines of
Looking ahead in 2021, domestic and
Mr. Qu Jiguang, Chairman and CEO of SSY Group Limited <\/b>said, “Facing
Net profits drop 46% to HK$612 million with final
dividend HK$0.05\/share
Adjust product mix actively; Strive for innovative
breakthroughs
Results summary:
Total revenue HK$4,261 million, representing a decrease of 8.1% y-o-y Net profits HK$612 million, representing a decrease of 46.1% y-o-y The Board resolved to pay final …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[60],"tags":[],"_links":{"self":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/13646"}],"collection":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/comments?post=13646"}],"version-history":[{"count":0,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/13646\/revisions"}],"wp:attachment":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/media?parent=13646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/categories?post=13646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/tags?post=13646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n2021 –\u00a0SSY Group Limited<\/a><\/b> (“SSY”
\nor the “Company”; Stock Code: 2005.HK) and its subsidiaries (together, the
\n“Group”) presents the annual results of the Company for the year ended 31 December
\n2020 (“2020” or “the year”).<\/p>\n
\n
<\/p>\n
\nGroup achieved a revenue of HK$4,261 million, representing a decrease of 8.1%
\nand the gross profit margin increased
\nby 1.5 percentage point to 63.6%. The Group achieved net profits of HK$612 million,
\nrepresenting a decrease of 46.1% compared with last year. During the year, the operational
\nactivities of various size of hospitals and various types of clinics in the PRC
\nwere severely disrupted by the epidemic and thus the number of patients
\nsubstantially decreased. Also, key product Moxifloxacin Hydrochloride &
\nSodium Chloride Injection was affected by national centralised procurement. Sales
\nvolume of intravenous infusion solutions, being the major products of the
\nGroup, dropped considerably. Sales volume of the intravenous infusion solutions
\nwas approximately 1,190 million bottles\/bags, representing a decrease of
\napproximately 23% compared to last year. Facing significant pressure from the
\nmarket, the Group responded actively by further securing and stabilizing its
\nmarket, and laid a solid market foundation for the rapid recovery of the
\nintravenous infusion solution business after the epidemic. On the other hand,
\nthe Group took effective measures to actively adjust its product mix and
\nfacilitate the rapid growth of businesses in ampoules, bulk pharmaceuticals and
\noral preparations, so as to further achieve the diversification of the business.<\/p>\n
\n
<\/p>\n
\nshare for year 2020, together with interim dividend HK$0.05 per share, total
\ndividend for full year of 2020 will be HK$0.10 per share, representing a
\ndecrease of approximately 9% from last year.<\/p>\n
\n
<\/p>\n
\nrepresenting a growth of 1.5 times compared to last year. During the year, the
\nGroup built a new production line designated for 10ml PP ampoule injections to
\nfurther expand production capacity of specialised ampoule products. In respect
\nof bulk pharmaceuticals business, through continuous optimization and
\nenhancement of production processes, preliminary production cost advantage has
\nrevealed, a new landscape is gradually formed with major bulk pharmaceuticals
\nand promising new products which are high value-added specialised bulk
\npharmaceuticals as coordinating development. Oral preparations business segment achieved preliminary results. After
\nimplementation of centralised procurement in the PRC, new products Cefdinir
\ncapsule and Prucalopride Succinate tablet were the first tender won by the Group.
\nThe PRC government has ordered the Group’s Abidol Hydrochloride capsule as a
\nbroad-spectrum antiviral drug through centralised procurement, which has played
\na positive role in this fight against the epidemic. The revenues of Abidol for
\nthe year amounted to RMB93.40 million, representing a significant increase of
\n13.5 times compared to last year. Export sales to foreign countries achieved a
\ngrowth despite the general trend, with increases in export revenue of 40.7% and
\nexport revenue of infusion solution of 10.2% compared to last year.<\/p>\n
\n
<\/p>\n
\ntransformation, upgrade and innovation development, the Group continuously
\nincreased its efforts in technological innovation. The Group’s pilot-testing
\nand industrialised support project for pharmaceutical research and development
\nplatform have been handed over for use in May 2020, which will facilitate the
\nGroup its industrial transformation and upgrade. Type I innovative drug NP-01,
\nthe Group’s first innovative drug, has received approval for clinical trial and
\nits clinical testing research have already commenced. During year 2020, 6
\nproducts with 7 specifications, including Prucalopride Succinate tablet (1mg,
\n2mg), Cefdinir capsule (0.1mg), Rosuvastatin Calcium Tablet (10mg), Doxofylline
\nInjection, Ropivacaine Hydrochloride Injection and Moxifloxacin Hydrochloride
\n& Sodium Chloride Injection, passed the Consistency Evaluation of Quality
\nand Efficacy of Generic Drugs in the PRC or were regarded as passing the
\nconsistency evaluation. During the year, 5 approvals for consistency evaluation
\nof injections have been obtained. Ciprofloxacin Lactate Injection was the first
\none of such product passing the consistency evaluation in the PRC while
\nFluconazole and Sodium Chloride Injection and Bromhexine Hydrochloride
\nInjection were the second ones of such products passing the consistency
\nevaluation in the PRC. The 250ml: 0.25g specification and 100ml:0.5g
\nspecification of Metronidazole and Sodium Chloride Injection were the first and
\nsecond one of such specifications passing the consistency evaluation in the PRC
\nrespectively.<\/p>\n
\n
<\/p>\n
\ninternational economy will remain complex and dynamic. Affected by the
\nnormality under novel coronavirus epidemic, the pressure arising from external
\nfactors may persist and bring new challenges to the Group’s operation and
\nsales. Facing numerous uncertainties, the Group will continue to keep its
\ncomposure, uphold its development focus and do its best in maintaining the
\nmomentum in sustainable and stable development of the Group. The Group will
\npromote development by innovation, and improve efficiency by management. The
\nGroup will maintain the leading position of our major products in intravenous
\ninfusion solution market. The Group will strive to achieve recovery growth of
\nintravenous infusion solution segment, with an estimated sales volume of 1,600
\nmillion bottles\/bags, representing an increase of approximately 34% from 2020.
\nThe Group will continue to maintain the fast growth of ampoule injection
\nbusiness so as to make ampoule business segment one of the principal businesses
\nof the Company soon. On the other hand, the Group will actively utilize the
\nproduction capacity of bulk pharmaceuticals and improve capacity utilization to
\nlay a solid foundation for the listing in the PRC. Moreover, the Group will
\ncontinue to make progress on implementation of innovative drug evaluations and
\nconsistency evaluations. We will adhere to the new product development idea of “combination
\nof generic and innovative drugs” with development of as injections the basis.
\nAt the same time, we will take into consideration of research and development
\nof new types of oral preparation, bulk pharmaceuticals and medical materials. Meanwhile,
\nthe Group strives to make new breakthroughs in the research and development of
\ninnovative drugs, push forward the phase I clinical trial of anti-tumor Type 1
\ninnovative drug NP-01, and conduct preliminary research on anti-liver fibrosis
\nType 1 innovative drug AND-9, anti-epileptic compound QO-83 and anti-tumor Type
\n2 chemical innovative drug Miriplatin.<\/p>\n
\n
<\/p>\n
\nthe risks and challenges persisting during the post-epidemic era, we are full
\nof confidence on the future development of the Group. Leveraging on the
\ncompetitive edges on our scale, quality, lean management and branding in the
\nindustry, we will firmly grasp development initiatives, keep the tenacity and
\nvitality from innovation development, and push forward high-quality development
\nof the Group. We will deliver more solid development results to bring
\nsatisfactory returns to our investors.”<\/p>\n<\/p><\/div>\n\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"